These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

602 related articles for article (PubMed ID: 33346445)

  • 1. [Informativeness of whole-body diffusion-weighted magnetic resonance imaging and positron emission tomography with computed tomography in follicular lymphoma].
    Nesterova ES; Yatsyk GA; Lutsik NS; Kravchenko SK; Sudarikov AB; Krasil'nikova IV; Gemdzhian EG; Kovrigina AM
    Ter Arkh; 2020 Sep; 92(7):55-62. PubMed ID: 33346445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of PET/MRI With PET/CT in the Evaluation of Disease Status in Lymphoma.
    Afaq A; Fraioli F; Sidhu H; Wan S; Punwani S; Chen SH; Akin O; Linch D; Ardeshna K; Lambert J; Miles K; Groves A; Kayani I
    Clin Nucl Med; 2017 Jan; 42(1):e1-e7. PubMed ID: 27607161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Whole-Body Diffusion-Weighted MRI Compared to
    Shapira-Zaltsberg G; Wilson N; Trejo Perez E; Abbott L; Dinning S; Kapoor C; Davila J; Smith B; Miller E
    Can Assoc Radiol J; 2020 May; 71(2):217-225. PubMed ID: 32062992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Whole-body MRI with diffusion-weighted imaging: a valuable alternative to contrast-enhanced CT for initial staging of aggressive lymphoma.
    Balbo-Mussetto A; Cirillo S; Bruna R; Gueli A; Saviolo C; Petracchini M; Fornari A; Lario CV; Gottardi D; De Crescenzo A; Tarella C
    Clin Radiol; 2016 Mar; 71(3):271-9. PubMed ID: 26749081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of whole-body MRI including diffusion-weighted sequences in the initial staging of breast cancer patients at high risk of metastases in comparison with PET-CT: a prospective cohort study.
    Hottat NA; Badr DA; Ben Ghanem M; Besse-Hammer T; Lecomte SM; Vansteelandt C; Lecomte SL; Khaled C; De Grove V; Salem Wehbe G; Cannie MM; Jani JC
    Eur Radiol; 2024 Jan; 34(1):165-178. PubMed ID: 37555959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Whole body MRI with Diffusion Weighted Imaging versus 18F-fluorodeoxyglucose-PET/CT in the staging of lymphomas.
    Maccioni F; Alfieri G; Assanto GM; Mattone M; Gentiloni Silveri G; Viola F; De Maio A; Frantellizzi V; Di Rocco A; De Vincentis G; Pulsoni A; Martelli M; Catalano C
    Radiol Med; 2023 May; 128(5):556-564. PubMed ID: 37145214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic performance of FDG-PET/MRI and WB-DW-MRI in the evaluation of lymphoma: a prospective comparison to standard FDG-PET/CT.
    Herrmann K; Queiroz M; Huellner MW; de Galiza Barbosa F; Buck A; Schaefer N; Stolzman P; Veit-Haibach P
    BMC Cancer; 2015 Dec; 15():1002. PubMed ID: 26699124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diffusion-weighted MRI in early chemotherapy response evaluation of patients with diffuse large B-cell lymphoma--a pilot study: comparison with 2-deoxy-2-fluoro- D-glucose-positron emission tomography/computed tomography.
    Wu X; Kellokumpu-Lehtinen PL; Pertovaara H; Korkola P; Soimakallio S; Eskola H; Dastidar P
    NMR Biomed; 2011 Dec; 24(10):1181-90. PubMed ID: 21387451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Whole-body MRI, FDG-PET/CT, and bone marrow biopsy, for the assessment of bone marrow involvement in patients with newly diagnosed lymphoma.
    Albano D; Patti C; Lagalla R; Midiri M; Galia M
    J Magn Reson Imaging; 2017 Apr; 45(4):1082-1089. PubMed ID: 27603267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison between whole-body MRI with diffusion-weighted imaging and PET/CT in staging newly diagnosed FDG-avid lymphomas.
    Albano D; Patti C; La Grutta L; Agnello F; Grassedonio E; Mulè A; Cannizzaro G; Ficola U; Lagalla R; Midiri M; Galia M
    Eur J Radiol; 2016 Feb; 85(2):313-8. PubMed ID: 26781135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diffusion-weighted MRI for staging and evaluation of response in diffuse large B-cell lymphoma: a pilot study.
    Siegel MJ; Jokerst CE; Rajderkar D; Hildebolt CF; Goyal S; Dehdashti F; Wagner Johnston N; Siegel BA
    NMR Biomed; 2014 Jun; 27(6):681-91. PubMed ID: 24700565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlations between functional imaging markers derived from PET/CT and diffusion-weighted MRI in diffuse large B-cell lymphoma and follicular lymphoma.
    Wu X; Pertovaara H; Korkola P; Dastidar P; Järvenpää R; Eskola H; Kellokumpu-Lehtinen PL
    PLoS One; 2014; 9(1):e84999. PubMed ID: 24454777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Whole-body MRI for staging and interim response monitoring in paediatric and adolescent Hodgkin's lymphoma: a comparison with multi-modality reference standard including
    Latifoltojar A; Punwani S; Lopes A; Humphries PD; Klusmann M; Menezes LJ; Daw S; Shankar A; Neriman D; Fitzke H; Clifton-Hadley L; Smith P; Taylor SA
    Eur Radiol; 2019 Jan; 29(1):202-212. PubMed ID: 29948084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Whole-body MRI versus an FDG-PET/CT-based reference standard for staging of paediatric Hodgkin lymphoma: a prospective multicentre study.
    Spijkers S; Littooij AS; Kwee TC; Tolboom N; Beishuizen A; Bruin MCA; Elias SG; van de Brug T; Enríquez G; Sábado C; Miller E; Granata C; de Lange C; Verzegnassi F; Greer MC; de Keizer B; Nievelstein RAJ
    Eur Radiol; 2021 Mar; 31(3):1494-1504. PubMed ID: 32880696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluorodeoxyglucose-Positron Emission Tomography Predicts Bone Marrow Involvement in the Staging of Follicular Lymphoma.
    St-Pierre F; Broski SM; LaPlant BR; Maurer MJ; Ristow K; Thanarajasingam G; Macon WR; Habermann TM; Witzig TE
    Oncologist; 2020 Aug; 25(8):689-695. PubMed ID: 32319706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Whole-body diffusion-weighted magnetic resonance imaging (WB-DW-MRI) vs choline-positron emission tomography-computed tomography (choline-PET/CT) for selecting treatments in recurrent prostate cancer.
    Conde-Moreno AJ; Herrando-Parreño G; Muelas-Soria R; Ferrer-Rebolleda J; Broseta-Torres R; Cozar-Santiago MP; García-Piñón F; Ferrer-Albiach C
    Clin Transl Oncol; 2017 May; 19(5):553-561. PubMed ID: 27796820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Whole body magnetic resonance with diffusion weighted sequence with body signal suppression compared to (18)F-FDG PET/CT in newly diagnosed lymphoma.
    Ferrari C; Minoia C; Asabella AN; Nicoletti A; Altini C; Antonica F; Ficco M; Guarini A; Maggialetti N; Rubini G
    Hell J Nucl Med; 2014; 17 Suppl 1():40-9. PubMed ID: 24392468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective comparison of 18-FDG PET/CT and whole-body diffusion-weighted MRI in the assessment of multiple myeloma.
    Mesguich C; Hulin C; Latrabe V; Lascaux A; Bordenave L; Hindié E; Marit G
    Ann Hematol; 2020 Dec; 99(12):2869-2880. PubMed ID: 32951093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.
    Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME
    Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.